Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | RORB | Q92753 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 3/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31456918 | 0.86 | NPC1 (0.50) | CYP2A6RORBHSD11B1NPC1RAB9A | |
| SCHEMBL14602199 | 0.84 | CNR2 (0.46) | CYP2A6RORBHSD11B1NPC1RAB9A | |
| SCHEMBL10802061 | 0.84 | CYP2A6 (0.54) | CYP2A6RORBHSD11B1MAOBDHODH | |
| SCHEMBL30122815 | 0.83 | PTGS2 (0.52) | RORBHSD11B1NPC1RAB9AALDH1A1 | |
| SCHEMBL23626276 | 0.82 | HSD11B1 (0.41) | CYP2A6RORBHSD11B1NPC1RAB9A | |
| SCHEMBL4904785 | 0.80 | KIF11 (0.48) | NPC1RAB9AALDH1A1L3MBTL1S1PR1 | |
| SCHEMBL31544740 | 0.80 | CYP2A6 (0.43) | CYP2A6RORBHSD11B1NPC1RAB9A | |
| SCHEMBL19318451 | 0.79 | DHODH (0.48) | RORBHSD11B1NPC1RAB9AALDH1A1 | |
| Trichloroethane SCHEMBL28457430 | 0.79 | CYP2A6 (0.58) | CYP2A6MAOBNPC1RAB9AALDH1A1 | |
| SCHEMBL27926227 | 0.79 | CYP2A6 (0.58) | CYP2A6RORBHSD11B1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119654309-A | Organic electroluminescent element and electronic device | 出光兴产株式会社 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024034659-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC APPLIANCE | 出光興産株式会社 | 2024-02-15 | — | — | WO | disclosed |
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10202354-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-01-25 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088662-A1 | FUNGICIDAL MIXTURES | BASF SE (DE) | 2012-04-12 | — | — | US | disclosed |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030029-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | CYP2A6 754/4885RORB 268/4885HSD11B1 312/4885 |
| US-20120088662-A1 | FUNGICIDAL MIXTURES | CYP51A1, CYP1A2, PFAS | CYP2A6 190/4885RORB 2447/4885HSD11B1 452/4885 |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | CYP2A6 194/4885RORB 67/4885HSD11B1 328/4885 |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | CYP2A6 1415/4885RORB 19/4885HSD11B1 737/4885 |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | CYP2A6 754/4885RORB 268/4885HSD11B1 312/4885 |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | DCK, DTYMK, TYMS | CYP2A6 2257/4885RORB 2064/4885HSD11B1 2627/4885 |
| US-20190099391-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | CYP2A6 958/4885RORB 297/4885HSD11B1 372/4885 |
| US-20110105463-A1 | 6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | GPR52, CD22, CD4 | CYP2A6 112/4885RORB 162/4885HSD11B1 3920/4885 |
| US-20180022707-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | CYP2A6 2951/4885RORB 283/4885HSD11B1 1196/4885 |
| US-11352321-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | CYP2A6 754/4885RORB 268/4885HSD11B1 312/4885 |
| US-20180022695-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | CYP2A6 754/4885RORB 268/4885HSD11B1 312/4885 |
| US-10202354-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | CYP2A6 2951/4885RORB 283/4885HSD11B1 1196/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | CYP2A6 958/4885RORB 297/4885HSD11B1 372/4885 |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | CYP2A6 1415/4885RORB 19/4885HSD11B1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.